Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.
As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Publication Alerts
Subscribe to receive alerts once a paper has been published by Oncotarget.
On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control.
This malicious action will be reported to the FBI.
On August 25, 2022, the Office of Science and Technology Policy announced a new government policy legislating the immediate public release of all United States-funded research publications by 2025. Learn more here and here.
On May 23, 2023, the Council of the European Union adopted conclusions on high-quality, transparent, open, trustworthy, and equitable scholarly publishing. The Council calls for immediate and unrestricted open access to publishing research involving public funds. Learn more.
At Oncotarget, we are committed to protecting the privacy of our users. This Privacy Policy outlines the information we collect, how it is used and the steps we take to ensure that your personal information remains confidential and secure.
Information Collection and Use
Oncotarget collects personal information such as your name, email address and other contact information when you create an account, subscribe to publication updates or participate in other activities on our site. We use this information to provide you with personalized content, improve our services and communicate with you about our journal.
Cookies and Tracking Technologies
Oncotarget uses cookies and other tracking technologies to collect information about your browsing activities. This information helps us to understand how our users use our site, improve our services and provide you with personalized content.
Children's Privacy
Oncotarget.com is intended for adults 18 years of age and older. We do not knowingly collect personally-identifying information from children under 13 years of age.
Disclosure of Information
Oncotarget does not sell, rent or share your personal information with third parties except as required by law. We may share your information with trusted service providers who work on our behalf, such as technical support and data analysis. These service providers are required to maintain the confidentiality of your information and may not use it for any purpose other than as described in this Privacy Policy.
Data Security
Oncotarget takes reasonable measures to protect your personal information from loss, misuse, unauthorized access, and alteration. We use encryption technologies, firewalls and other security measures to protect your information. However, no data transmission over the internet can be guaranteed to be 100% secure.
Changes to Privacy Policy
Oncotarget reserves the right to modify this Privacy Policy at any time. Any changes will be posted on this page, and your continued use of our site following any changes indicates your acceptance of the revised Privacy Policy.